393 related articles for article (PubMed ID: 18064531)
1. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
[TBL] [Abstract][Full Text] [Related]
2. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis.
Canon J; Bryant R; Roudier M; Osgood T; Jones J; Miller R; Coxon A; Radinsky R; Dougall WC
Bone; 2010 Jun; 46(6):1613-9. PubMed ID: 20215062
[TBL] [Abstract][Full Text] [Related]
4. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
Miller RE; Roudier M; Jones J; Armstrong A; Canon J; Dougall WC
Mol Cancer Ther; 2008 Jul; 7(7):2160-9. PubMed ID: 18606716
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
[TBL] [Abstract][Full Text] [Related]
6. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
Chanda D; Isayeva T; Kumar S; Siegal GP; Szafran AA; Zinn KR; Reddy VV; Ponnazhagan S
Mol Ther; 2008 May; 16(5):871-8. PubMed ID: 18388919
[TBL] [Abstract][Full Text] [Related]
7. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
9. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
11. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
[TBL] [Abstract][Full Text] [Related]
12. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
13. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
14. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
15. Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin.
Uehara H; Takahashi T; Izumi K
Int J Oncol; 2013 Aug; 43(2):365-74. PubMed ID: 23708710
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin in bone metastases: mathematical solution to the puzzle.
Ryser MD; Qu Y; Komarova SV
PLoS Comput Biol; 2012; 8(10):e1002703. PubMed ID: 23093918
[TBL] [Abstract][Full Text] [Related]
19. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]